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Abstract
A significant barrier to effective immune clearance of cancer is loss of antitumor cytotoxic T cell activity. Antibodies to block
pro-apoptotic/downmodulatory signals to T cells are currently being tested. Because invariant natural killer T cells (iNKT) can
regulate the balance of Th1/Th2 cellular immune responses, we characterized the frequencies of circulating iNKT cell
subsets in 21 patients with melanoma who received the anti-CTLA4 monoclonal antibody tremelimumab alone and 8
patients who received the antibody in combination with MART-126–35 peptide-pulsed dendritic cells (MART-1/DC). Blood T
cell phenotypes and functionality were characterized by flow cytometry before and after treatment. iNKT cells exhibited the
central memory phenotype and showed polyfunctional cytokine production. In the combination treatment group, high
frequencies of pro-inflammatory Th1 iNKT CD8+ cells correlated with positive clinical responses. These results indicate that
iNKT cells play a critical role in regulating effective antitumor T cell activity.
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Introduction
Invariant natural killer T cells (Type I NKT cells or iNKT) are
a subset of T cells that express a restricted repertoire of T-cell
receptors (TCR); in humans the iNKT TCR alpha chain presents
a Va24-JaQ rearrangement that preferentially pairs with a semi-
invariant Vb11 b-chain [1]. The iNKT TCR recognizes glycolipid
antigens presented by CD1d, a major histocompatibility complex-
like molecule present on the surface of antigen-presenting cells,
and that is highly expressed by myeloid dendritic cells (mDCs) [2–
4]. iNKT cells are actively recruited to infection sites, where they
respond to cytokines and interact with CD1d+ mDC [5]. In
response to stimuli, iNKT cells can release large amounts of
regulatory cytokines and are believed to play a pivotal role in the
determination of innate and adaptive immune system responses
[6]. iNKT cells can be subdivided into three subsets: CD4+, CD8+
and CD42/CD82 double negative (DN). The CD4+ subset has a
Th0 profile, being able to produce Th2 and Th1 cytokines such as
interleukin 4 (IL-4) and interferon gamma (IFN-c). DN iNKT cells
produce large amounts of Th1 cytokines such as INF-c and tumor
necrosis factor alpha (TNF-a), up-regulate perforin, and release
low levels of Th2 cytokines in response to stimuli [7]. Finally,
CD8+ iNKT cells constitute a Th1-only subset [7,8]. The balance
of CD4+ versus DN and/or iNKT CD8+ iNKT cells is thought to
be critical for proper modulation of immune responses to control
inflammatory processes, auto-immunity, and immune surveillance
of cancer [7,9,10].
The pivotal role of iNKT cells in the regulation of the immune
response makes them an attractive target for immunotherapy: the
frequency and functionality of iNKT cells is frequently altered in
patients with malignancies, autoimmune disorders, and viral
infections [11,12]. Blood iNKT cell frequencies fall in melanoma
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patients treated with radiation therapy [13,14] and a drastic
reduction in the frequency of iNKT cells capable of secreting IFN-
c has been observed in patients with advanced prostate cancer
[15]. Also, the iNKT number has been shown to increase in
cancer patients who responded successfully to non-immunological
therapies and the number and function of iNKT have been used
as prognostic markers in colonorectal, breast, renal cell carcinoma,
lung, and melanoma cancers [16,17]. The specific iNKT cell
activator, 9a-galactosyl ceramide (a-GalCer) is being utilized as
adjuvant in therapeutic vaccines therapies, and loaded onto
dendritic cells (DC) exhibited antitumor cytotoxicity against non-
small cell lung cancer [18–20]. As a consequence, the role of
iNKT cells in immune control and anti-tumor strategies is a
rapidly expanding field and is yielding promising results in the
elaboration of effective clinical protocols against cancer [21–23].
Dendritic cell (DC) vaccines have been tested in multiple clinical
trials for the treatment of patients with advanced melanoma
[24,25]. In the context of the interactions between antigen-
presenting cells (APC) and T cells, the initiation and maintenance
of T cell responses are critically regulated by co-stimulatory and
co-inhibitory signaling within the immunological synapse: resting
T cells recognize the co-stimulatory molecules CD80 (B7.1) and
CD86 (B7.2) presented by DC through the activating co-receptor
CD28. Upon activation, T cells upregulate the co-inhibitory
receptor CTLA4 (CD152). The interaction of CTLA4 on T cells
and B7 co-stimulatory molecules presented by DC inhibits TCR
signaling, IL-2 gene transcription and T-cell proliferation [26].
The use of CTLA4-specific human monoclonal antibodies like
tremelimumab or ipilimumab to block the interaction between
CTLA4 and B7 in order to increase T cell activation has been
extensively utilized in clinical trials for patients with cancer, and
the administration of tremelimumab to patients with metastatic
melanoma has consistently induced objective tumor regression in
approximately 10% of patients. Most of these responses are
extremely durable, some exceeding seven years [27–31]. Despite
years of clinical trials utilizing anti-CTLA4 antibodies and
dendritic cells, we still do not know the immune parameters that
correlate with positive clinical responses to these treatments;
uncovering such parameters would be invaluable for predicting the
prognosis of patients undergoing immunotherapy.
Since iNKT cells are a fundamental link between dendritic cells
and the adaptive immune system, we hypothesized that iNKT cells
may be implicated in the responses to CTLA4 blocking
monoclonal antibodies, in particular when administered together
with a DC vaccine. Here we studied the changes in the iNKT cell
populations in blood from patients treated with tremelimumab as
a single agent or in combination with DC vaccination. Our results
demonstrate that iNKT cells may play a role in the mechanism of
action of CTLA4 blocking antibodies when combined with a DC
vaccine and that high CD8+ iNKT frequency correlates with
positive clinical outcome.
Materials and Methods
Clinical Trials and Study Samples
Peripheral blood samples were obtained from 29 patients with
stage IIIc or IV melanoma treated at UCLA within two
independent clinical trials based on the administration of
tremelimumab (Pfizer, New London, CT). Written informed
consent was obtained for both trials [34]. Eight patients were
treated within a phase I clinical trial (from a total of sixteen) of a
dose escalation of intravenous infusion of tremelimumab (3–
15 mg/kg) administered concomitantly with three fixed doses of
16107 autologous DC pulsed with the MART-126–35 immunodo-
minant peptide epitope (MART-1/DC) manufactured as previ-
ously described (University of California Los Angeles Institutional
Review Board number (UCLA IRB#) 03-12-023, IND# 11579,
clinical trial registration number NCT0090896) [32,33,34]. The
study denomination of NRA and a patient-specific number was
assigned to these patients. The remaining 21 patients participated
in a phase II clinical trial of single agent tremelimumab
administered at 15 mg/kg every 3 months ((UCLA IRB)# 06-
06-093, IND# 100453, clinical trial registration number
NCT00471887) [33,34] (Figure 1). The study denomination GA
and a patient-specific number were assigned. A modified Response
Evaluation Criteria in Solid Tumors (RECIST, [32 to 35]) was
used to allocate an objective clinical response, where skin and
subcutaneous lesions evaluable only by physical exam were
considered measurable if adequately recorded using a photo-
graphic camera with a measuring tape or ruler; there was no
minimum size restriction for these lesions. A progressive disease–at
least a 20% increase in the sum of the longest diameter of target
lesions, taking as reference the smallest sum longest diameter
recorded since the treatment started or the appearance of one or
more new lesions; partial response–at least a 30% decrease in the
sum of the longest diameter of target lesions, taking as reference
the baseline sum longest diameter; stable disease–neither sufficient
shrinkage to qualify for partial response nor sufficient increase to
qualify for progressive disease, taking as reference the smallest sum
longest diameter since the treatment started; and complete
response–the disappearance of all target lesions [32–35]. Those
categories were used to classify the patients as responders (PR, CR)
or non-responders (PD, SD).
Sample Procurement and Processing
Pre-treatment leukapheresis and phlebotomies were carried out
for all the participants in both studies. The post-treatment
leukapheresis was performed one month after treatment for the
single agent tremelimumab trial (GA participants, median 38 days
post-treatment). In order to compare the two study treatments, we
chose a similar time point for both (Figure 1b), approximately one
month after treatment initiations. In all cases, a baseline sample
taken prior to any treatment served as control. In addition to the
post-dosing leukapheresis, NRA patients had post-treatment
peripheral blood samples taken around days: 31, 43, 60, 80, 95
and 118 during study participation. PBMC were isolated by Ficoll-
Hypaque (Amersham Pharmacia, Piscataway, NJ) gradient cen-
trifugation and cryopreserved in liquid nitrogen in RPMI (Gibco-
BRL, Gaithersburg, MD) supplemented with 20% (all percentages
represent v/v) heat-inactivated human AB serum (Omega
Scientific, Tarzana, CA) and 10% dimethylsulfoxide (DMSO,
Sigma, St. Louis, MO). Phenotype analyses were run using
aliquots of cryopreserved PBMC thawed and immediately diluted
with RPMI complete media consisting of 10% human AB serum,
and 1% penicillin, streptomycin and amphotericin (Omega
Scientific). Cells were washed and subjected to enzymatic
treatment with DNase (0.002%, Sigma) for 1 hour at 37uC. After
removing the DNase, PBMC were kept overnight in the incubator
at 37uC and 5%CO2 and stained for flow cytometry the next
morning.
Flow Cytometry Staining
Surface Staining: After resting, PBMC were centrifuged (468 g),
resuspended in 100 ml of adult bovine serum (Omega Scientific)
and stained for flow cytometry for 15 minutes at room
temperature as described in [32]. The reaction was stopped by
adding 3 ml of phosphate buffered saline without calcium and
magnesium (PBS) (Lonza, MD, USA). After centrifugation, the
iNKT Cells during Melanoma Immunotherapy
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pellet was resuspended in PBS, and the dead cell discriminator
7AAD was added to the PBMC. All cocktail combinations of pre-
conjugated antibodies were used at saturating conditions. (See
Table S2).
For intracellular cytokine staining (ICS), after resting overnight,
PBMCs were surface stained only for CD107a as described above.
Then, a concentration of 1.5 million per ml of PBMC were pulsed
with or without a final concentration of 300 IU/ml IL2 plus
50 ng/ml anti-CD3 (OKT-3; Centocor Ortho Biotech Inc.,
Horsham, PA) [36] for six hours. After the first hour of incubation,
1 ml of BDGolgiPlug (BDbioscience, San Jose, CA) was added.
After the stimulation, cells were put on ice for 5 minutes. Then,
surface staining for CD3, CD4, CD8, iNKT, and CD107a was
performed. After washing the excess of antibodies, cells were fixed
(BD Cytofix/Cytoperm), permeabilized (BD Perm/Wash Buffer),
and stained for IFNm, IL4, and IL10 following the manufacturer’s
instructions. All cocktail combinations of pre-conjugated antibod-
ies were used at saturating conditions (See Table S3). A
combination of anti-mouse IgG Negative Control Compensation
Particles (BD Biosciences) and PBMC were used for compensation
purposes. The fluorescence- minus-one (FMO) approach was used
to gate appropriately [32,58]. We acquired between 500,000 and
one million lymphocytes with a LSR II Flow Cytometer (BD
Biosciences). All flow data analyses were done with the FlowJo
software (Tree Star Inc., Asland, OR). The gating strategy was
displayed in (Figure S1a).
The absolute numbers of cells in the samples were monitored by
flow cytometry utilizing BD TrucountTM kits (BD Biosciences) as
indicated by the manufacturer.
iNKT was defined as double positive for TCR-Vb11 and TCR-
Va24.
Statistical Analysis
The statistical analyses are mainly descriptive because of the
small size of the population. Consequently, descriptive statistical
analyses were carried out with MinitabH Statistical Software (State
College, PA) and GraphPad Prism (GraphPad, San Diego, CA). In
all cases we collected between half and one million lymphocytes
through flow cytometry. Wilcoxon Sign Rank Test was used to
compare pre- and post-treatment tremelimumab effect. Mann
Whitney test was utilized to compare the analysis of results from
responders versus non-responders.
Results
Patient Characteristics, Response and Toxicities
21 patients received tremelimumab as a single agent (coded as
GA) and eight patients received tremelimumab together with
MART-1/DC (coded as NRA; Figure 1b and c). Table S1 shows
the baseline patient characteristics, the treatment received and the
clinical outcome. 14 of 27 patients (52%) had M1c metastatic
melanoma with visceral metastasis and/or high lactate dehydro-
genase (LDH). Overall, 7 patients (3 in the tremelimumab single
agent, and 4 in the tremelimumab plus MART-1/DC protocol)
had objective positive responses to the treatment, resulting in
sustained and durable tumor regression in 6 individuals. These 7
patients had either stage IIIc or M1a metastatic melanoma.
Toxicities were described previously [32–34].
Effects of Tremelimumab on T and iNKT Cell
Concentrations
In both clinical trials, we found a non-significant increase in the
percentage of CD3+ T cells after dosing (Figure 2A). On the other
hand, none of the treatments had any effect on the percentages of
CD4+ or CD8+ T cells (Figure 2B).
The proportion of circulating iNKT cells was not affected by
the treatments, (Figure 2C right panel). Incidentally, we measured
slightly higher frequencies of iNKT with a Th1 profile (iNKT DN
and iNKT CD8+ cells) at baseline in the tremelimumab plus
MART-1/DC study (p = 0.1796 and p = 0.6084 for iNKT DN
and iNKT CD8+ respectively; Figure 2D) although Fisher’s exact
test for high iNKT CD8+ percentages (above 15%) showed no
difference between both clinical trials at baseline (p = 0.5968).
Correlation of iNKT Cell Subsets to Clinical Response in
Combination Treatment
When we compared patient responses to the treatment of
tremelimumab plus MART-1/DC, we found that the individuals
with a positive clinical outcome (responders) showed higher total
numbers of iNKT cells than individuals who did not respond to
Figure 1. Description of the two tremelimumab clinical trials. (A) CONSORT flowchart. Tremelimumab alone (GA). (B) and tremelimumab plus
Mart1/DC (NRA). (C). Baseline is day 0, and numbers represent days after dosing that blood was drawn. NA-Not Aplicable.
doi:10.1371/journal.pone.0076829.g001
iNKT Cells during Melanoma Immunotherapy
PLOS ONE | www.plosone.org 3 October 2013 | Volume 8 | Issue 10 | e76829
the treatment (non-responders) at all the tested time points,
including baseline (p = 0.056; Figure 3A). The iNKT cell
frequencies remained unchanged in both groups after treatment
(Figure 3A). Further characterization of iNKT cell subsets revealed
that although the relative proportions of the different iNKT
subsets within each group were not modified by the treatment, the
total number of CD4+ iNKT cells in responders was lower than in
non-responders (mean 77671 cells/million T cells versus
1896120 cells/million T cells in non-responders; p,0.001;
Figure 3B). We also found a higher number of CD8+ iNKT cells
in responders (1546150 cells/million T cells, versus 1366 cells/
million T cells in non-responders; p,0.001; Figure 3C). The total
number of DN iNKT cells was also higher in responders, although
the difference was not significant (5966553 cells/million T cells
versus 3346224 cells/million T cells; p = 0.094; Figure 3D). We
also found that the percentage of total CD4+ T cells was slightly
higher in responders than in non-responders (p,0.001; Figure
S2A).
Phenotypes of iNKT Cells in Tremelimumab-Treated
Patients
We analyzed the maturation status of the different T-cell
populations by flow cytometry defining naı¨ve (N,
CCR7+CD45RA+), central memory (CM, CCR7+CD45RA2),
effector memory (EM, CCR72CD45RA2), and effector memory-
RA (EMRA, CCR72CD45RA+) T-cells [37]. We observed that
the majority of CD4+ iNKT cells had a CCR72CD45RA2 EM
phenotype (n = 21, median 50.25%), and the proportion of this
subpopulation was increased after treatment (median 57.21%;
p,0.01 compared to baseline, Figure 4A). The CD8+ iNKT cell
subset showed a non-significant increase, while the DN iNKT cell
subset showed a non-significant decrease of the EM phenotype
percentage after treatment (Figure 4B, C). DN and CD8+ iNKT
subsets, but not the CD4+ subset, presented sizable subpopulations
with the EMRA CCR72CD45RA+ phenotype whose frequencies
were unchanged by tremelimumab (Figure. 4B, C). Finally, a
substantial fraction of CD8+ iNKT cells showed the naı¨ve
phenotype, which was non-significantly reduced after dosing with
tremelimumab (Figure 4B).
Phenotype of iNKT Cells in Tremelimumab plus MART-1/
DC-Treated Patients
In patients treated with tremelimumab plus MART-1/DC, we
found the same profile in the maturation status of the three iNKT
subsets as seen in the tremelimumab-alone treatment with minor
differences: there were small populations of naı¨ve and central
memory phenotypes in CD4+ iNKT cells (Figure 4D) and lower
frequencies of EMRA phenotype in DN and CD8+ iNKT cells
Figure 2. CD3 and iNKT cells and subsets before and after tremelimumab single agent treatment. After gating by morphology, live cells
were gated on CD3+ T cells; CD3+ T cells (A), CD4+ and CD8+ (B); iNKT cells (double positive for TCR-Va24/Vb11; C); iNKT CD4+, iNKT CD8+ and iNKT DN
(D) subsets were analyzed before (open boxes in B and D panels) and after treatment (greyed boxes in B and D panels). In panels b and d, results are
presented as average of the percentage and standard deviation (sd) for both clinical trials (n = 21 for tremelimumab alone and n=8 for
tremelimumab plus Mart1/DC).
doi:10.1371/journal.pone.0076829.g002
iNKT Cells during Melanoma Immunotherapy
PLOS ONE | www.plosone.org 4 October 2013 | Volume 8 | Issue 10 | e76829
compared to the tremelimumab-alone treatment (Figure 4E, F).
The responder/non responder segregation presented a higher
percentage of naı¨ve, CM CD4+iNKT and CD8+iNKT in
responders (Figure 4G, H), and scarcity of DN iNKT (Figure 4F).
On the contrary, the percentage of EM subset was lower in
CD4+iNKT and CD8+iNKT of the responders (Figure 4G, H).
The same high percentage of EM was detected in DN iNKT
independent of treatment and response status. (Figure 4F, I).
To further characterize the iNKT cells from the tremelimumab
plus Mart1/DC trial, which presented a higher rate of positive
clinical responders (50%, four of eight) than the single agent
clinical trial (14%, three of twenty one), PBMC were evaluated by
multicolor phenotyping utilizing two additional panels. This
strategy enabled simultaneous analysis of additional activation
markers at each time point on all the iNKT cells subsets. Although
the percentage of all iNKT activation-based phenotypes remained
unchanged during and after treatment (Figure 5), we uncovered
different distributions of some phenotypes depending on the
clinical response (Table 1).
We utilized CD25 and HLA-DR plus PD1 staining to define
early (PD12: CD252HLA2DR+PD12 and CD25+HLA-
DR+PD12) and late (PD1+: CD252HLA2DR+PD1+) activated
T-cells. In all of the iNKT subsets, a small increase of the early
activated phenotype was found in clinical responders (Table 1, and
Figure 5A to F).
The frequency of the late activated phenotype was only present
in the CD4+ iNKT cells of the responders (36.8262.72)
(Figure 5G), but absent for CD8+ iNKT cells (Figure 5L). The
expression of the late activated phenotype in DN iNKT cells was
low but equally represented in responders and non-responders
(8.9463.31% versus 5.7661.10%) (Table 1, and Figure 5I).
A second panel was established to examine central memory
(CCR5+CD62L+CD1372), and effector
(CCR5+CD62L2CD1372) T cell phenotypes [38–40].
The central memory phenotype (CCR5+CD62L+CD1372) was
exhibited by all iNKT cells subsets (Figure 5J, K, L) and
significantly more frequent in Th1 iNKT cells from responders
(p = 0.023 and p = 0.051 for DN and CD8+ iNKT cells
respectively, Figure 5K, L). We detected comparable expression
of the effector phenotype in CD8+ iNKT cell in both responders/
non-responders (Table 1, and Figure 5O). However, the percent-
age of effector CD4+- and DN- iNKT cells was lower in
responders. (Table 1, and Figure 5M & N).
Figure 3. Percentage of iNKT cells and its subsets in samples taken from patients in the tremelimumab plus MART-1/DC study.
Evolution of iNKT cells and iNKT cells subsets during the treatment in the combined study in responders (circles) and non-responders (squares); (A)
number of iNKT per million T cells; (B) number of iNKT CD4+ per million T-cells; (C) number of iNKT CD8+ per million T-cells and; (D) number of iNKT
DN per million T-cells. In the Figure, regression lines for each data set are shown; error bars represent one sd from the mean for each point.
doi:10.1371/journal.pone.0076829.g003
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Finally, the expression of CD45RA and CD56 were utilized to
confirm the effector phenotypes (terminally differentiated effector
T cells are CD45RA+CD56+ [41]). This phenotype was detected
mainly at low expression in all iNKT subsets of responders, and
less than ten percent of the CD8+ iNKT non-responders (Table 1,
and Figure 5 P, R, S).
Altogether, these data show that although the proportions of
different phenotypes vary between the three iNKT subsets, there
Figure 4. Phenotyping of iNKT subsets. Frequencies of iNKT CD4 (A, D, G), iNKT CD8 (B, E, H), and DN (C, F, I) subsets. Upper panels (A, B, C),
tremelimumab alone clinical trial; middle and lower panels (D, E, F), tremelimumab plus Mart-1/DC trial. First and second row represented all iNKT
subsets analyzed for CCR7 and CD45RA expression before (B) and after (P) treatment for both clinical trials. The last row represented iNKT subsets
analyzed for CCR7 and CD45RA expression for responders (R) and non-responders (N) only for tremelimumab plus Mart-1/DC trial. EMRA= effector
memory RA; CM= central memory, and EM=effector memory.
doi:10.1371/journal.pone.0076829.g004
Table 1. Phenotyping characteristic of Tremelimumab plus MART1/DC patients segregated by responders (R) and non-responders
(NR) independent of the time points.
Early Activated (%) Late Activated (%) EFFECTORS (%) EFFECTORS Terminally differentiated (%)
CD4+ -iNKT R 9.8361.48 0.1060.11 13.0063.23 7.2662.42
NR 1.3060.27 36.8262.72 23.5366.71 1.7260.49
DN-iNKT R 5.4761.53 8.9463.31 13.3062.66 3.0660.42
NR 0.1860.06 5.7661.10 37.5768.83 0.2160.09
CD8+-iNKT R 11.0861.57 0.0460.03 30.8264.36 10.8361.58
NR 7.9261.96 0.0160.00 32.1466.50 6.6262.17
Early activated (CD252HLA2DR+PD12 & CD25+HLA2DR+PD12), n = 40 (NR) to 48 (R) time points; late activated (CD252HLA2DR+PD1+), n = 20 (NR) to 31 (R); effectors
(CCR5+CD62L+CD1372), n = 20 (NR) to 31 (R); and effectors terminally differentiated (CD45+CD56+), n = 20 (NR) to 31 (R).
doi:10.1371/journal.pone.0076829.t001
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was no significant difference in their distribution between
responders and non-responders.
Polyfunctionality of T and iNKT Cells in Tremelimumab
Plus MART-1/DC Treated Patients
We studied the functionality of T cells [42–44] after 95 days of
treatment compared to baseline in the tremelimumab plus Mart1/
DC protocol. Flow cytometric analysis included expression of
interleukin 4 (IL-4, marker for Th2), IFN-c (Th1), IL-10
(immunosuppressive), and CD107a (lysosomal-associated mem-
brane protein-1, LAMP-1, marker of cytotoxic degranulation). A
fold change of two was considered an actual change from baseline.
As expected, upon stimulation CD4+ and DN iNKT cells
exhibited a mixture of cytokine expression (Figure 6). The CD4+
iNKT cell subset presented a polyfunctional profile (two or more
intracellular markers; Figure 6A, D), mainly after stimulation in
responders. Only the non-responders secreted IL4/IL10 alone
(Figure 6A, D). DN iNKT cells showed polyfunctionality after
stimulation in responders, but not in non-stimulated cells from
non-responders; both responders and non-responders expressed a
combination of CD107a and IL4/IL10 (Figure 6B, D). CD8+
iNKT cells displayed some degree of polyfunctionality in the non-
responders, and a co-expression of IFNc and IL4/IL10 the
responders after stimulation (Figure 6C, D).
Total T cells showed the same profile as iNKT cells (Figure S4).
Discussion
This study was aimed to characterize iNKT cells in patients
with metastatic melanoma treated with tremelimumab as single
agent or in combination with MART-1/DC. We found that
following both treatments, the frequencies of total iNKT cells and
their subsets were altered, and that high iNKT CD8+ cell
frequencies correlated with successful outcomes in the combined
treatment. Since we compared the pre- and post-treatment iNKT
cell levels, age and sex, which are known to affect iNKT cell
frequency [16,17], were not confounding factors.
The most striking finding emerging from our work is the close
correlation between the positive clinical outcome for the
tremelimumab plus MART-1/DC treatment and the high
frequency of the CD8+ iNKT cell subset in the responders, with
a corresponding reduction in the frequency of the CD4+ iNKT cell
subset. This correlation was dependent on the presence of primed
dendritic cells, since it was not observed in the antibody-alone
treatment. Although some immune parameters in T cells and
monocytes have been variably associated with response to the
combination regimen [34,45]; although the small number of
patients, this is the first demonstration of a consistent immune
marker for treatment response: a high CD8+/CD4+ iNKT cell
ratio. Only one of the four responders in the combined treatment
received previous immunotherapy, another received chemother-
apy and the remaining two had no prior treatment [44], indicating
that previous immunotherapy did not cause the observed response.
Because of this, we hypothesize that the combination of high
CD8+/CD4+ iNKT cell ratio, tremelimumab, and the introduc-
tion of primed dendritic cells [46] led to the four responses, as both
clinical trials were based on tremelimumab and the long term
effects of tremelimumab as an anti-CTLA4 blockade antibody are
well described [29,30].
The frequencies for iNKT cells at baseline (0.01% for both
study arms) and the frequencies of CD8+ iNKT cells were typical
of those found in healthy individuals [11]. The CD8+ NKT cells
are the most variable subset of iNKT cells in humans [47,48],
usually representing between 10% and 15% of all iNKT cells in
healthy individuals [7]. In our study, the mean frequencies of
iNKT CD8+ fell within normal values and the percentages of
CD8+ iNKT cells above 15% at baseline was indistinguishable
Figure 5. Phenotype analysis of iNKT cells over time after tremelimumab plus MART-1/DC. Analysis of early activated
CD252HLA2DR+PD12 (A, B, C) and CD25+HLA2DR+PD12 (D, E, F), late activated CD252HLA2DR+PD1+ (G, H, I), central memory
CCR5+CD62L+CD1372 (J, K, L), effector CCR5+CD62L2CD1372 (M, N, O), and terminal differentiated CD45RA+CD56+ (P, R, S) iNKT cells. The
percentages of iNKT CD4+ (A, D, G, J, M, P), iNKT DN (B, E, H, K, N, R) and iNKT CD8+ (C, F, I, L, O, S) cells were quantified at different times during the
double treatment with tremelimumab plus MART-1/DC. Results expressed as means plus/minus sd and statistical significance. Squares represent non-
responders and circles responders to the treatment.
doi:10.1371/journal.pone.0076829.g005
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between both studies, indicating that high CD8+ iNKT cells in
responders was in fact related to treatment success.
As expected, we found that iNKT CD4+ cells secreted a mixture
of Th1 and Th2 cytokines in the same cell. This response was
independent of clinical response of the patients. Also, as previously
described [47,48], we found that iNKT CD8+ cells produced some
IFN-c and expressed CD107, but did produce IL-4/IL-10. We
speculated that the co-expression could be due to IFN-c with IL10
(not IL4) in response to a Th1 negative feed-back [49] and/or due
to the plasticity of iNKT cells [7]. Fold change cytokine
production was low in responders, which can be attributed to
the maturation status of the tremelimumab plus MART1/DC
iNKT cells. Those cells were mainly EM and EMRA of which
only approximately 10% were activated. Furthermore, the
presence of naı¨ve and CM found on CD4+ and CD8+ iNKT
cells did not contribute to cytokine production.
However, in agreement with our results it has been previously
described that high frequencies of iNKT cells, and more
importantly high frequencies of interferon gamma-producing
iNKT cells are correlated with tumor surveillance and increased
survival in non-small cell lung cancer patients, and an adjuvant
effect iNKT cells appears to be a determinant for tumor
eradication [19,20].
As we found significant positive response linked to high CD8+
iNKT cells in the tremelimumab plus MART-1/DC protocol, it is
reasonable to hypothesize that interactions between dendritic cells
and iNKT [50] cells play a fundamental role in the positive clinical
outcome. The dendritic cells that we examined are typically
immature dendritic cells [34], and an average of 88% expressed
CD1d (data not shown). Given the interaction of iNKT cells with
immature dendritic cells and their ability to mediate their
maturation through cytokines such as interferon gamma [51],
this interaction may be important given that mature dendritic cells
are more effective in helping to eliminate tumors [52].
We found that most iNKT cells express CCR5, CD45RA HLA-
DR and PD1, reflecting activated central memory and effector
memory phenotypes, in agreement with previous studies [11,53–
55]. Although none of the treatments affected the expression of
iNKT cell phenotypes or cytokine secretion, we observed
segregation of the activation markers when we compared subjects
that responded to the combined treatment with non-responders.
CD25, HLA-DR, CCR5, and CD45RA showed higher expression
in responders, while PD1 was over-represented in non-responders.
Figure 6. Functionality of iNKT subsets after tremelimumab plus Mart-1/DC treatment. Intracellular staining of IFNc, IL4, IL10 and CD107a
in iNKT cells after tremelimumab plus Mart-1/DC treatment between responders (blue) and non-responders (grey) were measured in PBMC
stimulated with OKT-3 plus IL2 for six hours. Y axis displayed fold change of CD4+- DN- CD8+-iNKT cells after treatment. X axis showed the different
cytokines expressed by the cells. Dot line showed two fold change with respect to baseline, and any bar over the two fold is considered a change.
doi:10.1371/journal.pone.0076829.g006
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These results reinforce the idea that higher T cell activation
correlates with better cancer control [56–58]. Furthermore, the
finding that responders to combination treatment had this
phenotype before treatment suggests that they may be useful
predictors of clinical response. It is yet unclear whether strategies
using iNKT cells as adjuvants in immunotherapy approaches via
administration of alpha-galactosyl ceramide to expand iNKT cells
or differentiation of iNKT cells from pluripotent or embryonic
cells [59–61] will be effective.
In conclusion, it is becoming evident that iNKT cells can play a
pivotal role in anti-cancer immunity. We have characterized
peripheral iNKT cells in two different tremelimumab clinical trials
for patients with advanced melanoma, finding that responders to
tremelimumab plus Mart1/DC treatment had higher frequency of
the Th1 type CD8+ iNKT cells and a lower frequency Th2/anti-
inflammatory CD4+ iNKT cells than non-responders. Further
studies will be required to confirm that the CD8+/CD4+ iNKT
cell ratio predicts a positive outcome in dendritic cell cancer
immunotherapies, and whether such therapies would benefit from
adjuvant protocols to selectively drive activation and proliferation
of CD8+iNKT cells.
Supporting Information
Figure S1 Gating strategy. (A) Surface staining. Live cells
(7AAD2) were gated on morphology (Lymphocytes & monocytes)
based on side and forward light scattering. 7AAD2/CD3+ T cells
were separated into three subsets. CD4+, CD8+, and iNKT
(double positive for TCR-Va24/Vb11). iNKT were further
separated into iNKT-CD8+; iNKT CD4+,and iNKT-DN (double
negative CD82/CD42). These T-cell subsets were then examined
for different activation markers, in this example: CD25 & HLA-
DR (Activation markers), and PD1 (exhausted cells). Bolean gates
were applied to these subsets. (B) ICS. After doublet elimination,
lymphocytes were gated on morphology, based on scatter. CD3+ T
cells were separated into three subsets: CD4+, CD8+, and iNKT
(double positive for TCR-Va24/Vb11). iNKT were further
separated into iNKT-CD8+; iNKT CD4+,and iNKT-DN (double
negative CD82/CD42). These T-cell subsets were then examined
for CD107a, interferon-gammma (IFNc), CD107a, and a
combination of IL4/IL10.
(TIF)
Figure S2 CD3 T cells after tremelimumab exposure.
Percentage of CD3+CD4+ (light gray) and CD3+CD8+ (dark gray)
T cells before (B) and at different time-points of CTLA4 dosing in
the tremelimumab as single agent treatment (***p,0.001).
(TIF)
Figure S3 Functionality of T subsets after tremelimu-
mab plus Mart-1/DC treatment. Intracellular staining of
IFNc, IL4, IL10 and CD107a in iNKT cells after tremelimumab
plus Mart-1/DC treatment between responders (blue) and non-
responders (grey) were measured in PBMC stimulated with OKT-
3 plus IL2 for six hours. Y axis displayed fold change of CD4+- and
CD8+- T cells after treatment. X axis showed the different
cytokines expressed by the cells. Dot line showed two fold change
with respect to baseline, and any bar over the two fold is
considered a change.
(TIF)
Table S1 Patient characteristics.
(DOCX)
Table S2 Antibody combinations for multicolor surface
immune phenotyping of NRA and GA patients.
(PDF)
Table S3 Antibody combinations for ICS of NRA
patients. In parenthesis the clone used.
(PDF)
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